Completely revised and updated, the 2001 PDR provides FDA–approved drug information on more than 4,000 prescription drugs, over 2,100 full–color, actual–size photos of medicines for instant identification, and important data on over 250 drug manufacturers. New medicines, new drug interaction data, the most recent side effects findings, and certain drugs now removed from the market make it absolutely critical that medical and healthcare professionals keep up–to–date with the very latest prescription drug information. The 2001 PDR contains: the newest drugs–which drugs are indicated for the diagnosed condition; how different drugs interact; latest findings on side effects caused by the prescribed drug; recommended dosages; clinical pharmacology; pediatric use; contraindications; FDA use–in–pregnancy ratings; and more. Hundreds of new drugs added including: Relenza & Tamiflu, Tequin & Avelox, Synercid I.V., Celebrex, Norvir, Protonix, Elexon and Zyvox. New larger trim size allows dramatically improved readability. 3,000+ pages.
Not only are today′s prescription drugs vital to the patient′s well–being, but their effectiveness and safety can impact the integrity and security of all involved healthcare professionals as well.
New in ′99 – The new 54th edition comprises 3,000 pages, is extensively illustrated in full colour, and indexes some 4,000 drugs. Important data on over 250 drug manufacturers is also presented.
In today′s fast–moving healthcare field, it is vital that the physician keeps abreast of:
? The latest drugs – which drugs are indicated for the diagnosed condition
? How different drugs interact
? Latest findings on side effects caused by the prescribed drug
? Recommended dosages
? Clinical pharmacology
? Paediatric use
? Contraindications
? FDA use–in–pregnancy ratings
? And much, much more .
The 2000 PDR? guarantees the physician the security and safety of having up–to–the–minute official FDA–approved information on over 4,000 prescription drugs and important data on over 250 drug manufacturers.
Among the new drugs featured in this edition are Xenical, the first of a new class of drugs called lipase inhibitors, indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced–calorie diet; Avandia, a new member of a class of antidiabetic agents which acts primarily by increasing insulin sensitivity in muscle and adipose tissue; Celebrex and Vioxx, two new non–steroidal anti–inflammatory drugs; iEnbrel, a new treatment option for rheumatoid arthritis; Pletal, a phosphodieterase III inhibitor that reveribly inhibits platelet aggregation; and Agenerase, a new selective synthetic inhibitor of HIV–protease.
Section 1 – Manufacturers′ Index
A listing of all pharmaceutical manufacturers participating in Physicians′ Desk Reference?. All addresses, telephone numbers, and emergency contacts are given.
Section 2 – Brand and Generic Name Index – This index lists every product alphabetically by both brand and generic name.
Section 3 – Product Category Index – Lists products by prescribing category – allowing quick and easy identification of all agents with a given therapeutic use or mechanism of action.
Section 4 – Product Identification Guide – Presents full–colour, actual size photographs of tablets and capsules, plus pictures of a variety of other dosage forms and packages.
Section 5 – Product Information – The main section of the book. Includes entries for over 2,200 pharmaceuticals.
Completely revised and updated, the 2001 PDR provides FDA–approved drug information on more than 4,000 prescription drugs, over 2,100 full–color, actual–size photos of medicines for instant identification, and important data on over 250 drug manufacturers. New medicines, new drug interaction data, the most recent side effects findings, and certain drugs now removed from the market make it absolutely critical that medical and healthcare professionals keep up–to–date with the very latest prescription drug information. The 2001 PDR contains: the newest drugs–which drugs are indicated for the diagnosed condition; how different drugs interact; latest findings on side effects caused by the prescribed drug; recommended dosages; clinical pharmacology; pediatric use; contraindications; FDA use–in–pregnancy ratings; and more. Hundreds of new drugs added including: Relenza & Tamiflu, Tequin & Avelox, Synercid I.V., Celebrex, Norvir, Protonix, Elexon and Zyvox. New larger trim size allows dramatically improved readability. 3,000+ pages.
Not only are today′s prescription drugs vital to the patient′s well–being, but their effectiveness and safety can impact the integrity and security of all involved healthcare professionals as well.
New in ′99 – The new 54th edition comprises 3,000 pages, is extensively illustrated in full colour, and indexes some 4,000 drugs. Important data on over 250 drug manufacturers is also presented.
In today′s fast–moving healthcare field, it is vital that the physician keeps abreast of:
? The latest drugs – which drugs are indicated for the diagnosed condition
? How different drugs interact
? Latest findings on side effects caused by the prescribed drug
? Recommended dosages
? Clinical pharmacology
? Paediatric use
? Contraindications
? FDA use–in–pregnancy ratings
? And much, much more .
The 2000 PDR? guarantees the physician the security and safety of having up–to–the–minute official FDA–approved information on over 4,000 prescription drugs and important data on over 250 drug manufacturers.
Among the new drugs featured in this edition are Xenical, the first of a new class of drugs called lipase inhibitors, indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced–calorie diet; Avandia, a new member of a class of antidiabetic agents which acts primarily by increasing insulin sensitivity in muscle and adipose tissue; Celebrex and Vioxx, two new non–steroidal anti–inflammatory drugs; iEnbrel, a new treatment option for rheumatoid arthritis; Pletal, a phosphodieterase III inhibitor that reveribly inhibits platelet aggregation; and Agenerase, a new selective synthetic inhibitor of HIV–protease.
Section 1 – Manufacturers′ Index
A listing of all pharmaceutical manufacturers participating in Physicians′ Desk Reference?. All addresses, telephone numbers, and emergency contacts are given.
Section 2 – Brand and Generic Name Index – This index lists every product alphabetically by both brand and generic name.
Section 3 – Product Category Index – Lists products by prescribing category – allowing quick and easy identification of all agents with a given therapeutic use or mechanism of action.
Section 4 – Product Identification Guide – Presents full–colour, actual size photographs of tablets and capsules, plus pictures of a variety of other dosage forms and packages.
Section 5 – Product Information – The main section of the book. Includes entries for over 2,200 pharmaceuticals.
